Significance of familial history of prostate cancer to traditional prognostic variables, genetic biomarkers, and recurrence after radical prostatectomy

Urology

Volumn 51, Issue 6, 1998, Pages 970-976

  Bauer, John J ^b   Srivastava, Shiv ^b   Connelly, Roger R ^b   Sesterhenn, Isabell A ^b   Preston, David M ^b   McLeod, David G ^b   Moul, Judd W ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; KI 67 ANTIGEN; PROSTATE SPECIFIC ANTIGEN; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CELL DIFFERENTIATION; FAMILY HISTORY; GENETIC MARKER; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RECURRENCE RISK; RISK FACTOR; SURVIVAL RATE;

AGED; ANTIGENS, CD34; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032100448     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00103-4     Document Type: Article

References (27)

1. Krain L.S. Some epidemiologic variables in prostatic carcinoma in California. Prev Med. 3:1974;154-159.
2. Meikle A.W., Smith J.A., West D.W. Familial factors affecting prostatic cancer risk and plasma sex-steroid levels. Prostate. 6:1985;121-128.
3. Steinberg G.D., Carter B.S., Beaty T.H., et al. Family history and the risk of prostate cancer. Prostate. 17:1990;337-347.
4. Spitz M.R., Currier R.D., Fueger J.J., et al. Familial patterns of prostate cancer a case-control analysis . J Urol. 146:1991;1305-1307.
5. Carter B.S., Bova G.S., Beaty T.H., et al. Hereditary prostate cancer epidemiologic and clinical features . J Urol. 150:1993;797-802.
6. Cussenot O., Valeri A., Meria P., et al. Genetic aspects in cancers of the prostate. Pathol Biol. 44:(Paris):1996;737-743.
7. Ghadirian P., Howe G.R., Hislop T.G., et al. Family history of prostate cancer a multi-center case-control study in Canada . Int J Cancer. 70:1997;679-681.
8. Aprikian A.G., Bazinet M., Plante M., et al. Family history and the risk of prostatic carcinoma in a high risk group of patients. J Urol. 154:1995;404-406.
9. Whittemore A.S., Wu A.H., Kolonel L.N., et al. Family history and prostate cancer risk in black, white, and Asian men in the United States and Canada. Am J Epidemiol. 141:1995;732-740.
10. Nippon S., Masuda H., Sato J., et al. An analysis of familial prostate cancer. Nippon Hinyokika Gakkai Zasshi. 86:1995;1483-1487.
11. Keetch D.W., Rice J.P., Suarez B.K., et al. Familial aspects of prostate cancer a case control study . J Urol. 154:1995;2100-2102.
12. Gronberg H., Damber L., Damber J.E. Familial prostate cancer in Sweden A nationwide register cohort study . Cancer. 77:1996;138-143.
13. McCahy P.J., Harris C.A., Neal D.E. Breast and prostate cancer in the relatives of men with prostate cancer. Br J Urol. 78:1996;552-556.
14. Hayes R.B., Liff J.M., Pottern L.M., et al. Prostate cancer risk in U.S. blacks and whites with a family history of cancer. Int J Cancer. 60:1995;361-364.
15. Smith J.R., Freije D., Carpten J.D., et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science. 274:1996;1371-1374.
16. Keetch D.W., Humphrey P.A., Smith D.S., et al. Clinical and pathological features of hereditary prostate cancer. J Urol. 155:1996;1841-1843.
17. Bastacky S.I., Wojno K.J., Walsh P.C., et al. Pathological features of hereditary prostate cancer. J Urol. 153:1995;987-992.
18. Kupelian P.A., Kupelian V.A., Witte J.S., et al. Family history of prostate cancer in patients with localized prostate cancer an independent predictor of treatment outcome . J Clin Oncol. 15:1997;1478-1480.
19. Bettencourt MC, Bauer JJ, Sesterhenn IA, et al: Angiogenesis is a prognostic marker of prostate cancer recurrence after radical prostatectomy. J Urol (in press).
20. Moul J.W., Bettencourt M.C., Sesterhenn I.A., et al. Protein expression of p53, bcl-2 and Ki-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. Surgery. 120:1996;159-167.
21. Partin A.W., Oesterling J.E. The clinical usefulness of prostatic specific antigen update . J Urol. 152:1994;1358-1368.
22. Gleason D.F. Histological grading and clinical staging of prostate carcinoma. Tannenbaum M. Urologic Pathology The Prostate . 1977;171-197 Lea & Febiger, Philidelphia.
23. Mostofi F.K., Sesterhenn I.A., Sobin L.H. Histological Typing of Prostate Tumors. 1980;World Health Organization, Geneva.
24. Obovi M., Wheeler T.M., Scardino P.T. The new American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer Clinicopathologic correlations . Cancer. 74:1994;104-114.
25. Kupelian P. Prostate cancer patients with a positive family history fare worse after surgery. Mod Med. 65:1997;35.
26. Gronberg H., Isaacs S.D., Smith J.R., et al. Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus. JAMA. 278:1997;1251-1255.
27. Rodriguez C., Calle E.E., Miracle-McMahill H.L., et al. Family history and risk of fatal prostate cancer. Epidemiology. 8:1997;653-657.